These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27195774)

  • 1. Ferric carboxymaltose with or without erythropoietin in anemic patients with hip fracture: a randomized clinical trial.
    Bernabeu-Wittel M; Romero M; Ollero-Baturone M; Aparicio R; Murcia-Zaragoza J; Rincón-Gómez M; Monte-Secades R; Melero-Bascones M; Rosso CM; Ruiz-Cantero A;
    Transfusion; 2016 Sep; 56(9):2199-211. PubMed ID: 27195774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: a randomized contolled trial. The PAHFRAC-01 project.
    Bernabeu-Wittel M; Aparicio R; Romero M; Murcia-Zaragoza J; Monte-Secades R; Rosso C; Montero A; Ruiz-Cantero A; Melero-Bascones M;
    BMC Musculoskelet Disord; 2012 Feb; 13():27. PubMed ID: 22353604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.
    Calleja JL; Delgado S; del Val A; Hervás A; Larraona JL; Terán Á; Cucala M; Mearin F;
    Int J Colorectal Dis; 2016 Mar; 31(3):543-51. PubMed ID: 26694926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
    Spahn DR; Schoenrath F; Spahn GH; Seifert B; Stein P; Theusinger OM; Kaserer A; Hegemann I; Hofmann A; Maisano F; Falk V
    Lancet; 2019 Jun; 393(10187):2201-2212. PubMed ID: 31036337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
    Makharadze T; Boccia R; Krupa A; Blackman N; Henry DH; Gilreath JA
    Am J Hematol; 2021 Dec; 96(12):1639-1646. PubMed ID: 34653287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty.
    Bisbe E; Moltó L; Arroyo R; Muniesa JM; Tejero M
    Br J Anaesth; 2014 Sep; 113(3):402-9. PubMed ID: 24780615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
    Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
    JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study.
    Rineau E; Chaudet A; Chassier C; Bizot P; Lasocki S
    Transfusion; 2016 Mar; 56(3):673-81. PubMed ID: 26748489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia.
    Litton E; Baker S; Erber W; French C; Ferrier J; Hawkins D; Higgins AM; Hofmann A; Keulenaer BL; Farmer S; McMorrow J; Olynyk J; Richards T; Towler S; Webb S;
    Crit Care Resusc; 2014 Dec; 16(4):285-90. PubMed ID: 25437223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
    Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss.
    Salvadori U; Sandri M; Melli C; Polese F; Simeoni M; Capelli S; Al-Khaffaf A
    Transfusion; 2016 Nov; 56(11):2720-2726. PubMed ID: 27600706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding.
    Ballester-Clau R; Torres Vicente G; Voltà-Pardo T; López-Barroso L; Cucala-Ramos M; Reñé-Espinet JM; Planella de Rubinat M
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):116-122. PubMed ID: 30335628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
    Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Shapiro MJ; Corwin MJ; Colton T;
    JAMA; 2002 Dec; 288(22):2827-35. PubMed ID: 12472324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
    Luporsi E; Toledano A; Spaeth D; Scotté F; Espié M; Perot S; Duvillié L; Pithois Merli I; Bugat R
    Support Care Cancer; 2017 Mar; 25(3):973-982. PubMed ID: 27915456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial.
    Laso-Morales MJ; Vives R; Vallejo-Tarrat A; Caló N; Valle-Beltran A; Pontes C
    Trials; 2019 Jan; 20(1):23. PubMed ID: 30616657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.